Sign in4 stories
The company said topline results from the pivotal lanifibranor trial are expected in the fourth quarter of 2026, as it reports a comprehensive refinancing and updated cash runway.
SEC filing
The regulatory and quality veteran joins as Candel prepares a fourth-quarter 2026 BLA submission for aglatimagene besadenovec.
SEC filing
The MASH treatment trial finished its final 72-week patient visit, with topline results still expected in the fourth quarter of 2026.
SEC filing
The MASH drug developer said Benecchi will oversee launch preparations for lanifibranor ahead of Phase 3 data expected in the fourth quarter of 2026.
SEC filing